STL Index for: Lidocaine
This update covers Pembrolizumab IV injection (Keytruda®), Hyaluronic acid gel filler (Juvéderm Volbella® XC), Biosimilar of infliximab (Flixabi®), Ceftaroline fosamil for IV infusion (Teflaro®), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® + Lidocaine), Ixekizumab SC injection (Talz®), Adapalene gel 0.1% (Differin® Gel), C1 esterase inhibitor(human) for IV infusion (Berinert®)
An overview and update of skin treatments introduced in 2015: Quick overview of drug name, indications and regulatory status. Deoxycholic acid injection, 5-fluorouracil 0.5% + salicylic acid 10% solution, Adapalene 0.3% + benzoyl peroxide 2.5% gel, and more are covered.
Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)
Update on Varicose vein n-butyl-2-cyanoacrylate adhesive polymer (VenaSeal™ Closure System), Dermal filler + calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse®), Dalbavancin for IV injection (Xydalba™), Pembrolizumab for IV infusion (Keytruda®)
Vulvovaginal diseases commonly are inadequately diagnosed and treated. This article discusses the important role dermatologists play in identifying irregular presentations, recognizing skin problems, and addressing itch, pain, and inflammation.
An overview and update of skin conditions and treatments introduced in 2010: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% lotion (Differin®), Clindamycin phosphate 1.2% + tretinoin 0.025% gel (Veltin™) and many other drugs are covered.
Drug Treatments for Skin Disease Introduced in 2010. Adapalene 0.1% lotion (Differin®), Drospirenone / ethinyl estradiol / levomefolate calcium + levomefolate calcium tablets (Beyaz™) and many other drugs are covered.
Update on Hyaluronic acid dermal filler + 0.3% lidocaine JUVÉDERM® XC, Hyaluronic acid dermal filler + 0.3% lidocaine RESTYLANE®-L PERLANE®-L, and news on labeling changes regarding possible hepatic effects of diclofenac sodium topical gel 1% (Voltaren® Gel).
Poly-L-lactic acid is a filler recently approved by the US FDA for the correction of facial lipoatrophy in patients infected with the human immunodeficiency virus (HIV). Currently, poly-L-lactic acid, sold under the brand name Sculptra™ (Dermik), is the only product approved by the FDA specifically for this indication.
Postherpetic neuralgia is a serious complication of herpes zoster that has a predilection for older individuals. Postherpetic neuralgia is often associated with significant morbidity, and it can cause insomnia, fatigue, depression and interference with daily activities in affected individuals.
Update on: Alendronate Fosamax Alitretinoin Panretin Gel 0.1% Malathion Ovide 0.5% Lotion Abacavir Sulfate Ziagen Interferon alpha-2a Roferon-A Lidocaine Patch 5% Lidoderm Pexiganan acetate Locilex cream 1% Aminolevulinic acid Levulan Photodynamic Therapy Ketoconazol Teva Antiviral Agents Antirejection Therapy
There are three electrolysis modalities. In galvanic electrolysis, a direct electric current is passed down a needle inserted into the hair follicle, destroying the follicle. In thermolysis a high frequency alternating current is passed down the needle and produces destructive heat.
Update on: Mupirocin Bactroban® Roxithromycin Rulid® Temoporfin Foscan®Fluticasone propionate Cutivate® Cream 17-Beta-Estradiol Vagifem® Itraconazole injection Sporanox® IV injection Becaplermin Regranex® Gel 0.1% Lidocaine/prilocaine EMLA® cream
In this article, we examine the other approaches to PHN management. Claims have been made for products ranging from vitamins to snake venom for patients who develop PHN.